Literature DB >> 11865085

Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose.

Marie-Carmen Muniz Martinez1, Joëlle Nortier, Pierre Vereerstraeten, Jean-Louis Vanherweghem.   

Abstract

BACKGROUND: Renal failure after ingestion of Chinese herbs between 1990 and 1992 was related to the replacement of Stephania tetrandra by Aristolochia fangchi (ST-AF), containing nephrotoxic and carcinogenic aristolochic acids. However, the relationship between ST-AF and renal failure is still a matter of debate. We therefore tested the impact of the ST-AF ingested dose on the progression of renal function deterioration.
METHODS: Analysis of medical charts and prescriptions between 1990 and 1992 was carried out to determine the presence of risk factors for kidney failure and the cumulative dose of pill components. Individual progression rate of renal impairment was studied by the time-course of the inverse of blood creatinine level (1/P(creat)).
RESULTS: Patients were divided into an end-stage renal disease (ESRD) group (n=44) and a chronic renal failure (CRF) group (n=27) according to their P(creat) at the time of this study. The mean number of risk factors (+/-SD) was equally distributed within both groups (1.50+/-0.18 vs 1.59+/-0.17, P=0.74). Patients from the ESRD group ingested significantly higher cumulative doses of ST--AF (192+/-13.1 g vs 138+/- 16.3 g), Magnolia officinalis, (80.1+/-6.3 g vs 59.8+/-11.7 g), diethylpropion (14.7+/-1.4 g vs 10.0+/-1.4 g) and fenfluramine (14.1+/-1.6 g vs 8.7+/-1.3 g). In the ESRD group, some patients who had received steroids had a slower progression to ESRD than the others. In multiple regression analysis, ST-AF emerged as the only significant drug predicting the slope of the progression of renal failure. Moreover, hypothesizing a linear dose-response relationship, the risk of developing ESRD linearly increased with ST-AF doses.
CONCLUSIONS: The relationship between the cumulative ST-AF dose and the renal failure progression rate confirms that regular ingestion of Aristolochia sp. extracts is causally involved in the onset of chronic interstitial nephropathy leading to ESRD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865085     DOI: 10.1093/ndt/17.3.408

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  18 in total

1.  Genetic loci that affect aristolochic acid-induced nephrotoxicity in the mouse.

Authors:  Thomas A Rosenquist
Journal:  Am J Physiol Renal Physiol       Date:  2011-03-23

2.  Microarray analysis reveals the inhibition of nuclear factor-kappa B signaling by aristolochic acid in normal human kidney (HK-2) cells.

Authors:  Ya-yin Chen; Su-yin Chiang; Hsiu-ching Wu; Shung-te Kao; Chien-yun Hsiang; Tin-yun Ho; Jaung-geng Lin
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

3.  A meta-analysis of medicinal plants to assess the evidence for toxicity.

Authors:  Sarah Chen; Amandio Vieira
Journal:  Interdiscip Toxicol       Date:  2010-06

Review 4.  Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date.

Authors:  Jean-Pierre Cosyns
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 5.  Risk assessment of upper tract urothelial carcinoma related to aristolochic acid.

Authors:  Felicia Wu; Tianxiu Wang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-05       Impact factor: 4.254

6.  Misdiagnosis and undiagnosis due to pattern similarity in Chinese medicine: a stochastic simulation study using pattern differentiation algorithm.

Authors:  Arthur Sá Ferreira
Journal:  Chin Med       Date:  2011-01-12       Impact factor: 5.455

Review 7.  Balkan endemic nephropathy-current status and future perspectives.

Authors:  Nikola M Pavlović
Journal:  Clin Kidney J       Date:  2013-06

Review 8.  Exploiting the nephrotoxic effects of venom from the sea anemone, Phyllodiscus semoni, to create a hemolytic uremic syndrome model in the rat.

Authors:  Masashi Mizuno; Yasuhiko Ito; B Paul Morgan
Journal:  Mar Drugs       Date:  2012-07-23       Impact factor: 6.085

9.  Development of a chronic kidney disease model in C57BL/6 mice with relevance to human pathology.

Authors:  Linghong Huang; Alessandra Scarpellini; Muriel Funck; Elisabetta A M Verderio; Timothy S Johnson
Journal:  Nephron Extra       Date:  2013-01-11

10.  Combination of extracts from Aristolochia cymbifera with streptomycin as a potential antibacterial drug.

Authors:  Willer F Silva; Samyra G Cecílio; Cintia Lb Magalhães; Jaqueline Ms Ferreira; Antonio H Tótola; Jose C de Magalhaes
Journal:  Springerplus       Date:  2013-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.